ACTRN12621000689875已完成1 期
A Randomised, Double-Blind, Vehicle-Controlled Study of the Safety and Tolerability of BTX 1702 in Patients with Papulopustular Rosacea
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 133
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •#1. Patient has a diagnosis at Screening and Baseline of moderate or severe papulopustular rosacea of the face with:
- •a. 15 to 75 (inclusive) inflammatory lesions (papules/pustules) on the face.
- •b. Rosacea severity of moderate (3) or severe (4) on a 5-point static investigator global
- •assessment for papules & pustules (IGA-PP)
- •c. CEA score of 3 or 4 (moderate or severe) assessed on the face.
- •d. No more than 5 large open comedones.
- •#2. An independent reviewer will review screening photographs to confirm eligibility of the patient for enrolment. No patient may be randomized prior to the confirmation of eligibility by the independent reviewer.
- •#3. Patient has less than or equal to 2 nodular lesions (greater than or equal to 5 mm in diameter).
- •#4. Patient agrees to abstain from use of marijuana or cannabidiol (CBD) products throughout the study.
- •#5. Male patients and their partners must agree and commit to use a barrier method of
- •contraception throughout the study and for 90 days after last study medication application.
排除标准
- •#1. Patient has used any marijuana products, via any route, within 4 weeks prior to the
- •Screening Visit. A positive urine drug screen (UDS) for tetrahydrocannabinol (THC) will
- •exclude the patient. Patient may be deemed eligible if the UDS identifies patient-reported, prescribed medications or appropriate levels of alcohol, as determined by the investigator.
- •#2. Patient has any significant active infection at Baseline.
- •#3. Patient has known human immunodeficiency viruses (HIV) infection or hepatitis B or C.
- •#4. Patient has initiated a hormonal method contraception within 3 months of Baseline or plans to discontinue or change during the study or changed product within 3 months of Baseline.
- •#5. Patient has used topical acne or rosacea treatments, including metronidazole, azaleic acid, sulfacetamide, salicylic acid, benzyl peroxide, ivermectin, bromonidine, or oxymetazoline within 4 weeks of Baseline.
- •#6. Patient has used systemic retinoids or high dose (less than 10,000 IU/day) Vitamin A, within 90 days of Baseline.
- •#7. Patient has used topical or systemic antibiotics within 4 weeks of Baseline.
- •#8. Patient has used topical (facial) or systemic anti-inflammatories for more than 14
- •consecutive days in the 4 weeks prior to Baseline.
- •#9. Patient has used topical (facial) or systemic corticosteroids 4 weeks prior to Baseline.
- •#10. Patient has used vasodilating agents (e.g., anti-hypertensives, erectile dysfunction
- •medications, nitroglycerin) 6 weeks prior to Baseline.
- •#11. Patient has used alpha-adrenergic receptor-blocking agents 6 weeks or alpha-adrenergic agonists 4 weeks prior to Baseline.
- •#12. Patient has ocular rosacea and/or blepharitis/meibomianitis and requires treatment by an ophthalmologist during the study.
- •#13. Patient has sunburns, unevenness in skin tones, tattoos, scars, excessive hair (e.g., beard, moustache), freckles, birthmarks, moles, oedematous lesions or other skin damage or abnormality that would result in the inability to perform study assessments.
- •#14. Patient has an active or potentially recurring skin conditions(s) other than rosacea that may interfere with the rosacea assessment of or require topical or systemic treatment that may affect treatment assessments.
- •#15. Patient has used systemic or other immunosuppressive medications within 4 weeks of the Baseline Visit (inhaled corticosteroid less than or equal to 1000 µg daily dose is acceptable).
- •#16. Patient has used phototherapy 14 days prior to Baseline or has had excessive sun exposure with intent to sunbathe or tan or use artificial tanning agents.
- •#17. Patient has undergone dermatologic procedures to the face including laser, intense pulsed light, chemical peels, salabrasion, dermabrasion or botulinum toxin injection within 4 weeks of the Baseline Visit.
- •#18. Patient has other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, acne or atopic dermatitis.
- •#19. Patient has participated in another investigational medication or device research study within 30 days of the Screening Visit or five half-lives of the medication, whichever is longer.
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82